197 related articles for article (PubMed ID: 1356055)
21. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
22. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
[TBL] [Abstract][Full Text] [Related]
23. A case of Graves' disease in association with hemiagenesis of the thyroid gland.
Rashid HI; Yassin J; Owen WJ
Int J Clin Pract; 1998 Oct; 52(7):515-6. PubMed ID: 10622098
[TBL] [Abstract][Full Text] [Related]
24. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis.
Izumi Y; Hidaka Y; Tada H; Takano T; Kashiwai T; Tatsumi KI; Ichihara K; Amino N
Clin Endocrinol (Oxf); 2002 Jul; 57(1):51-8. PubMed ID: 12100069
[TBL] [Abstract][Full Text] [Related]
25. Thyroid-stimulating and eye muscle antibodies in Graves' disease and Graves' orbitopathy.
Kahaly G; Grübl M; Moncayo R; Schilling S; Weber P; Beyer J; Krause U
Dev Ophthalmol; 1989; 20():68-78. PubMed ID: 2574117
[No Abstract] [Full Text] [Related]
26. Hypercalcemia due to Graves' disease in a patient with thyroid hemiagenesis.
Kebapçilar L; Akinci B; Demir T; Bayraktar F; Yeşil S
Kulak Burun Bogaz Ihtis Derg; 2009; 19(3):159-62. PubMed ID: 19857196
[TBL] [Abstract][Full Text] [Related]
27. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
28. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of postpartum thyrotoxicosis by serum thyroglobulin: usefulness of a new multisite immunoradiometric assay.
Hidaka Y; Nishi I; Tamaki H; Takeoka K; Tada H; Mitsuda N; Amino N
Thyroid; 1994; 4(3):275-8. PubMed ID: 7833663
[TBL] [Abstract][Full Text] [Related]
31. Graves' disease: diagnostic and therapeutic challenges (multimedia activity).
Kahaly GJ; Grebe SK; Lupo MA; McDonald N; Sipos JA
Am J Med; 2011 Jun; 124(6):S2-3. PubMed ID: 21605717
[TBL] [Abstract][Full Text] [Related]
32. Graves' disease coexisted with resistance to thyroid hormone: a case report.
Akahori H; Usuda R
J Med Case Rep; 2021 Sep; 15(1):473. PubMed ID: 34560890
[TBL] [Abstract][Full Text] [Related]
33. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
34. Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment.
Hegedüs L; Hansen JM; Bech K; Kampmann JP; Jensen K; Andersen E; Hansen P; Karstrup S; Bliddal H
Acta Endocrinol (Copenh); 1984 Dec; 107(4):482-8. PubMed ID: 6151328
[TBL] [Abstract][Full Text] [Related]
35. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study.
Carlé A; Knudsen N; Pedersen IB; Perrild H; Ovesen L; Rasmussen LB; Laurberg P
Eur J Endocrinol; 2013 Nov; 169(5):537-45. PubMed ID: 23935127
[TBL] [Abstract][Full Text] [Related]
36. Poorly Differentiated Thyroid Carcinoma Coexisting with Graves' Disease Involving T3 Thyrotoxicosis due to Increased D1 and D2 Activities.
Okazaki-Hada M; Maruoka A; Yamamoto M; Ito M; Hirokawa M; Nishikawa M; Akamizu T; Miyauchi A; Toyoda N
Thyroid; 2021 Oct; 31(10):1592-1596. PubMed ID: 34278816
[No Abstract] [Full Text] [Related]
37. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
38. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
Kung AW; Lau KS; Kohn LD
J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin.
Rapoport B; Greenspan FS; Filetti S; Pepitone M
J Clin Endocrinol Metab; 1984 Feb; 58(2):332-8. PubMed ID: 6141176
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of thyrotropin receptor antibody (TRAb) levels in Graves' disease.
Wilson R; McKillop JH; Thomson JA
Ann Clin Biochem; 1990 Nov; 27 ( Pt 6)():601-2. PubMed ID: 1981965
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
